MichaelAaron Flicker, founder and CEO of XenoPsi Ventures, walks through the impact that GLP-1 drugs are having on consumer behavior and how some of the top consumer food brands are responding. Flicker examines how GLP-1 users impact the behavior of entire households, the changing dynamic of the restaurant experience and where GLP-1 users are spending outside of grocery stores and eating out.